Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS

A pediatric label expansion built on pharmacokinetic bridging data has cleared FDA review, extending Joenja (leniolisib) to children aged 4–11 years weighing at least 27 kg, the first approved treatment for activated PI3K delta syndrome (APDS) in this age group. For regulatory affairs leads tracking pediatric extensions under PREA and orphan drug frameworks, the approval signals that PK-bridging from a small open-label cohort can satisfy the agency when adult efficacy data are robust and the PK profile is consistent across age bands.

Joenja was first approved in 2023 for patients 12 years and older at a fixed dose of 70 mg orally twice daily. The new pediatric indication introduces weight-based dosing of 40, 50, or 70 mg twice daily, approximately 12 hours apart. The dose selection was supported by Study LE 3301, a single-arm, open-label study in 8 patients, where pharmacokinetic data demonstrated no clinically significant difference between patients younger or older than 12 years, a bridging conclusion that underpinned the approval without a separate placebo-controlled efficacy trial in the younger cohort.

The original efficacy foundation rests on Study 2201 (NCT02435173), a 12-week, blinded, randomized, placebo-controlled study of 31 patients aged 12 and older. Of those, 21 received leniolisib 70 mg twice daily and 10 received placebo. Co-primary endpoints were lymphoproliferation reduction and immunophenotype normalization measured by naïve B-cell percentage. By day 85, the leniolisib arm showed lymph node size reduction and a 37% improvement in naïve B-cell counts versus placebo, indicating correction of the underlying PI3Kδ-driven immune defect.

APDS is caused by mutations in PIK3CD or PIK3R1 genes, impairing PI3K delta protein function and disrupting normal white blood cell development. The condition presents with recurrent sinopulmonary infections, lymphoproliferation causing airway and gastrointestinal obstruction, cytopenias, and elevated lymphoma risk, a burden that makes early intervention in pediatric patients clinically significant.

From a safety and labeling standpoint, QA and pharmacovigilance teams should note that the most common adverse events in the 4–11 cohort included abdominal pain, respiratory tract infection, diarrhea, headache, cough, nausea, rhinitis, and alopecia. Joenja carries a contraindication in patients with moderate-to-severe hepatic impairment, a restriction that carries over from the adult label and will require age-appropriate monitoring protocols at dispensing sites.

Joenja holds orphan drug designation, rare pediatric disease designation, and priority review status, a designation stack that rare disease sponsors will study closely as a template for accelerating pediatric extensions where adult PK and efficacy data can anchor a bridging strategy.

The measurable checkpoint ahead is real-world PK consistency in the 4–11 population at commercial scale, which post-marketing commitments will likely be required to confirm.

Source: FDA Drugs News and Events via FDA.gov, 11 September 2026.